Compare · LLY vs NUVL
LLY vs NUVL
Side-by-side comparison of Eli Lilly and Company (LLY) and Nuvalent Inc. (NUVL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NUVL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.30T.
- LLY has been more active in the news (45 items in the past 4 weeks vs 2 for NUVL).
- Both have 25 recent analyst ratings on file.
- Company
- Eli Lilly and Company
- Nuvalent Inc.
- Price
- -
- -
- Market cap
- $1.30T
- -
- 1M return
- +7.61%
- -
- 1Y return
- +31.79%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 45
- 2
- Recent ratings
- 25
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Nuvalent Inc.
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest LLY
- Gold, Silver and Crude Slide Hard as Volatility Jumps on the Week
- Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)
- Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)
- Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)
- Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)
- Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)
- Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)
- Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)
- Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)
- Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)
Latest NUVL
- FDA Approval for NELKARMI issued to NUVALENT
- FDA Approval for NELKARMI issued to NUVALENT
- SEC Form 15-12G filed by Nuvalent Inc.
- FDA Approval for JIDEYTRO issued to NUVALENT INC
- Amendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.
- Director by Deputization Flynn James E returned $427,056 worth of Class A Common Stock - Restricted Stock Units to the company (3,444 units at $124.00) and returned $2,138,807,800 worth of shares to the company (17,248,450 units at $124.00) (SEC Form 4) to satisfy withholding tax
- Director Meyers Michael L. returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Balcom Alexandra returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Srivastava Sapna returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Oliger Christy J. returned 6,091 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)